Arch Therapeutics Announces Formation of Medical Advisory Board

FRAMINGHAM, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced the formation of a medical advisory board comprised of respected wound care professionals across multiple medical specialties, including vascular surgery, podiatric medicine, and foot and ankle surgery. The Company believes that the Medical Advisory Board will support the strategic alignment of patient, payor, and provider goals to help advance the ongoing commercialization of its AC5® Advanced Wound System.

“We are honored to draw on the expertise of these industry leaders as we continue to pursue our mission of creating a better patient experience for those with challenging chronic and acute surgical wounds, while simultaneously improving value for both payors and medical practices,” stated Terrence W. Norchi, MD, President and Chief Executive Officer of Arch. “We believe the combined experience and expertise of this Medical Advisory Board will help drive the continued adoption and utilization of AC5, as well as potentially shape our work for years to come.”

Arch welcomes the following six members to its Medical Advisory Board:

  • Dr. Gregory A. Bohn, MD, FACS, ABPM/UHM, MAPWCA, CWSP, board-certified in General Surgery and Hyperbaric Medicine, and President of the American Board of Wound Healing;
  • Dr. Matthew G. Garoufalis, DPM, FASPS, FACPM, CWS, board-certified in Podiatric Medicine and Foot and Ankle Surgery, Chief Medical Officer of Advanced Oxygen Therapy Inc., and key opinion leader on diabetic foot care, lower extremity wound care, and limb salvage;
  • Dr. John C. Lantis, MD, FACS, Chief and Professor of Surgery at Mount Sinai West Hospital and the Icahn School of Medicine, and key opinion leader on limb salvage and lower extremity wound healing;
  • Dr. Brock A. Liden, DPM, FABWH, FAPWCA, board-certified in Podiatry, attending physician at WAFL, and expert lecturer on wound care, podiatric medicine, surgery, and practice management; and,
  • Dr. Terry A. Treadwell, MD, FACS is a vascular surgeon, Medical Director of the Institute of Advanced Wound Care in Montgomery, Alabama, and renowned lecturer on chronic wound care.

About Arch Therapeutics, Inc.

Located in Framingham, Massachusetts, Arch is a biotechnology company with a novel approach to stop bleeding (hemostasis), control leaking (sealant), and manage wounds during surgery, trauma, and interventional care. Arch is developing wound care and biosurgical products based on an innovative self-assembling peptide technology platform with the goal of improving healing outcomes for patients. Arch has received regulatory clearance to market AC5® Advanced Wound System in the United States and AC5® Topical Hemostat in Europe. Arch’s development stage product pipeline includes AC5-GTM for endoscopic resection of gastrointestinal tumors, AC5-V® for hemostasis during vascular surgery, and AC5 Surgical Hemostat for general surgical hemostasis, among others.1,2

For more information, please visit or follow us on TwitterInstagram, and LinkedIn.